Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

NCT05999396 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT05999396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05999396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
Lead sponsor
German Cancer Research Center
Phase
Phase 1
Overall status
Recruiting
Start date
January 12, 2024
Completion date
March 31, 2027
Enrollment
89 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, colorectal cancer, penile carcinoma, sarcoma